---
title: "Organogenesis says RCT shows Affinity lifts venous leg ulcer closure rates at weeks 12 and 16"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293969176.md"
description: "Organogenesis reported peer-reviewed results from a randomized clinical trial of Affinity for complex venous leg ulcers, published in the Journal of Wound Care. The 206-patient study demonstrated that Affinity combined with standard care significantly improved wound closure outcomes at weeks 12 and 16 compared to standard care alone. These findings support broader clinical evidence for chronic wounds, potentially strengthening the product's adoption case."
datetime: "2026-07-27T20:06:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293969176.md)
  - [en](https://longbridge.com/en/news/293969176.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293969176.md)
generator: "portal-rs"
---

# Organogenesis says RCT shows Affinity lifts venous leg ulcer closure rates at weeks 12 and 16

-   Organogenesis reported peer-reviewed results from a randomized clinical trial of Affinity in complex venous leg ulcers. \* Results were published in the Journal of Wound Care; no separate future presentation was disclosed. \* Affinity with standard care improved wound closure outcomes versus standard care alone in hard-to-heal ulcers. \* The 206-patient study supports broader clinical evidence across chronic wound types, strengthening the product’s coverage and adoption case. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271605PRIMZONEFULLFEED9798643) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ORGO.US](https://longbridge.com/en/quote/ORGO.US.md)

## Related News & Research

- [MediWound DSMB sees no safety issues, backs EscharEx Phase III venous leg ulcer trial continuing unchanged](https://longbridge.com/en/news/298907432.md)
- [Rohto starts Phase II trial of RE-01 cell therapy for refractory ischemic leg ulcers](https://longbridge.com/en/news/299125173.md)
- [NEW JAMA NETWORK OPEN STUDY SHOWS GIVING LESS IV FLUIDS DURING SURGERY CAN BE BENEFICIAL FOR PATIENTS](https://longbridge.com/en/news/299070641.md)
- [Treace Medical presents 5-year ALIGN3D study showing Lapiplasty bunion procedure recurrence as low as 0.8%](https://longbridge.com/en/news/299366583.md)
- [Spectral AI showcases DeepView burn assessment system at Southern Regional Burn Conference](https://longbridge.com/en/news/299230026.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**